title: Effect of resveratrol and in combination with 5-FU on murine liver cancer.
abstract: OBJECTIVE
  To study the anti-tumor effect of resveratrol and in combination with 5-FU on murine liver cancer.
  
  
  METHODS
  Transplantable murine hepatoma22 model was used to evaluate the anti-tumor activity of resveratrol (RES) alone or in combination with 5-FU in vivo. H22 cell cycles were analyzed with flow cytometry.
  
  
  RESULTS
  Resveratrol could inhibit the growth of murine hepatoma22, after the mice bearing H22 tumor were treated with 10 mg/kg or 15 mg/kg resveratrol for ten days, and the inhibition rates were 36.3% (n = 10) and 49.3% (n = 9), respectively, which increased obviously compared with that in control group (85+/-22 vs 68+/-17, P<0.01). RES could induce the S phase arrest of H22 cells, and increase the percentage of cells in S phase from 59.1% (n = 9) to 73.5% (n = 9) in a dose-dependent manner (P<0.05). The enhanced inhibition of tumor growth by 5-FU was also observed in hepatoma22 bearing mice when 5-FU was administered in combination with 10 mg/kg resveratrol. The inhibition rates for 20 mg/kg or 10 mg/kg 5-FU in combination with 10 mg/kg resveratrol were 77.4% and 72.4%, respectively, compared with the group of 20 mg/kg or 10 mg/kg 5-FU alone, in which the inhibition rates were 53.4% and 43.8%, respectively (n = 8). There was a statistical significance between the combination group and 5-FU group.
  
  
  CONCLUSIONS
  RES could induce the S phase arrest of H22 cells and enhance the anti-tumor effect of 5-FU on murine hepatoma22 and antagonize its toxicity markedly. These results suggest that resveratrol, as a biochemical modulator to enhance the therapeutic effects of 5-FU, may be potentially useful in cancer chemotherapy.
authors.affiliation: Department of Hepatobiliary Surgery, First Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China. victorywu2000@163.com
authors.forename: Sheng-Li
authors.initials: SL
authors.lastname: Wu
authors.forename: Zhong-Jie
authors.initials: ZJ
authors.lastname: Sun
authors.forename: Liang
authors.initials: L
authors.lastname: Yu
authors.forename: Ke-Wei
authors.initials: KW
authors.lastname: Meng
authors.forename: Xing-Lei
authors.initials: XL
authors.lastname: Qin
authors.forename: Cheng-En
authors.initials: CE
authors.lastname: Pan
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D018797:Cell Cycle Proteins / Q000187:drug effects; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005472:Fluorouracil / Q000494:pharmacology / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology / Q000627:therapeutic use*; D015996:Survival Rate
chemical_list: D016588:Anticarcinogenic Agents; D000964:Antimetabolites, Antineoplastic; D018797:Cell Cycle Proteins; D013267:Stilbenes; D000077185:Resveratrol; D005472:Fluorouracil